XTalks

SEPTEMBER 14, 2022

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. One of the first options made available for such purposes was Botox from Allergan, brought to health practitioners’ offices in 1989. A Novel Botox Competitor. Bringing Daxxify into Offices.

Botox 98

Botox FDA Approval Cosmetics Clinical Trials 98

XTalks

AUGUST 2, 2023

Paxlovid was first authorized under the FDA Emergency Use Authorization in December 2021 ; however, it has received FDA approval on May 25, 2023. pneumoniae serotypes) replaced the company’s first pneumococcal conjugate vaccine Prevnar (PCV7, approved by the FDA in February 2000) in a February 2010 FDA approval.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

AUGUST 1, 2021

Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0 Global Botox Cosmetic net revenues were $584 million, an increase of over 100.0 to $6.14; Raises 2021 Adjusted Diluted EPS Guidance Range from $12.37 Global net revenues from the neuroscience portfolio were $1.459 billion, an increase of 98.8

Botox 52

Botox Cosmetics Trials Clinical Trials 52